Abstract
When, in 1966, radioactive vitamin D3 of high specific activity was prepared, a reasonable approach became available to the question of whether vitamin D was active as such or whether it had to be first converted to metabolically active forms. Thus, Lund and DeLuca1 demonstrated the existence of polar metabolites that not only proved to be more effective than vitamin D3 in the treatment of rickets but also could act much more rapidly than the parent vitamin D3 in initiating intestinal calcium transport and in initiating bone mineral mobilization, both fundamental actions of the vitamin. This discovery . . .